Proteomic studies coupled with RNAi methodologies can shed further light on the downstream effects of telomerase in glioma

Cancer Investigation

Volumn 29, Issue 2, 2011, Pages 113-122

  Thakkar, Dipti ^a   Shervington, Leroy ^a   Shervington, Amal ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Brain tumors; Cancer biomarkers; Gene expression; Molecular biology

Indexed keywords

CYTOSKELETON PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; TELOMERASE; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; DOWN REGULATION; EPENDYMOMA; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL CULTURE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RNA INTERFERENCE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HUMANS; NEOPLASM PROTEINS; PROTEOMICS; RNA INTERFERENCE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TELOMERASE; VIMENTIN;

EID: 79251518918     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.543212     Document Type: Article

References (52)

1. Argyriou AA, Kalofonos HP. Molecularly targeted therapies for malignant gliomas. Mol Med 2009;15(3-4): 115-122.
2. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, Deen DF. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008;10(2):112-120.
3. Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G, Dawson T, Shervington L. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res 2007;1134(1):45-52.
4. Shay JW, Wright WE. Hallmarks of telomeres in ageing research. J Pathol 2007;211(2):114-123.
5. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996;56(3):645-650.
6. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999;13(15):2091-2104.
7. Cong Y, Wright WE, Shay, JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66(3):407-425.
8. Mazzucchelli GD, Gabelica V, Smargiasso N, Fleron M, Ashimwe W, Rosu F, Pauw-Gillet, M. D., Riou J, Pauw, E. D. Proteome alteration induced by hTERT transfection of human fibroblast cells. Proteome Sci 2008;6(12):1-13.
9. Shervington A, Cruickshanks N, Wright H, Atkinson-Dell, R., Lea R, Roberts G, Shervington, L. Glioma: what is the role of c-Myc, hsp90 and telomerase? Mol Cell Biochem 2006;283(1-2): 1-9.
10. Cruickshanks N, Shervington L, Patel R, Munje C, Thakkar D, Shervington, A. Can hsp90alpha-Targeted siRNA combined with TMZ be a future therapy for glioma? Cancer Invest 2010;28(6):608-614.
11. Thakkar D, Shervington, A. Proteomics: the tool to bridge the gap between the facts and fables of telomerase. Crit Rev Oncog 2008;14(4):203-215.
12. Shervington A, Patel, R. Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. Oligonucleotides 2008;18(4):365-374.
13. Shervington A, Pawar V, Menon S, Thakkar D, Patel, R. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol Biol Rep 2009;36(5):1181-1186.
14. Huang GP, Pan ZJ, Huang JP, Yang JF, Guo CJ, Wang YG, Zheng Q, Chen R, Xu YL, Wang GZ, Xi YM, Shen D, Jin J, Wang, J. F. Proteomic analysis of human bone marrow mesenchymal stem cells transduced with human telomerase reverse transcriptase gene during proliferation. Cell Prolif 2008;41:625-644.
15. Sobel, M. E. Differential expression of the 67 kDa laminin receptor in cancer. Semin Cancer Biol 1993;4(5):311-317.
16. Castronovo, V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 1993;13(1):1-30.
17. Martignone S, Menard S, Bufalino R, Cascinelli N, Pellegrini R, Tagliabue E, Andreola S, Rilke F, Colnaghi, M. I. Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 1993;85(5):398-402.
18. Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner, R. Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol 2009;22(12):1600-1611.
19. Woo IS, Jang HS, Eun SY, Kim HJ, Ham SA, Kim HJ, Lee JH, Chang KC, Kim JH, Han CW, Seo, H. G. Ran suppresses paclitaxel-induced apoptosis in human glioblastoma cells. Apoptosis 2008;13(10):1223-1231.
20. Grabowski DT, Pieper RO, Futscher BW, Deutsch WA, Erickson LC, Kelley, M. R. Expression of ribosomal phosphoprotein PO is induced by antitumor agents and increased in Mer-human tumor cell lines. Carcinogenesis 1992;13(2):259-263.
21. Shi Y, Zhai H, Wang X, Wu H, Ning X, Han Y, Zhang D, Xiao B, Wu K, Fan, D. Multidrug-resistance-associated protein MGr1-Ag is identical to the human 37-kDa laminin receptor precursor. Cell Mol Life Sci 2002;59(9):1577-1583.
22. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage, H. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 1998;37(3):105-116.
23. Zhang JT, Liu, Y. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 2007;33(8):741-756.
24. Rush MG, Drivas G, D'Eustachio, P. The small nuclear GTPase Ran: how much does it run? Bioessays 1996;18(2):103-112.
25. Rhee HJ, Kim GY, Huh JW, Kim SW, Na, D. S. Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem 2000;267(11):3220-3225.
26. Condeelis J, Singer RH, Segall, J. E. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol 2005;21:695-718.
27. Dizhoor, A. Site-directed and natural mutations in studying functional domains in guanylyl cyclase activating proteins (GCAPs). Adv Exp Med Biol 2002;514:291-301.
28. Iwasaki T, Murata-Hori, M., Ishitobi S, Hosoya, H. Diphosphorylated MRLC is required for organization of stress fibers in interphase cells and the contractile ring in dividing cells. Cell Struct Funct 2001;26(6):677-683.
29. Tohtong R, Phattarasakul K, Jiraviriyakul A, Sutthiphongchai, T. Dependence of metastatic cancer cell invasion on MLCK-catalyzed phosphorylation of myosin regulatory light chain. Prostate Cancer Prostatic Dis 2003;6(3):212-216.
30. Feldner JC, Brandt, B. H. Cancer cell motility-on the road from cerbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 2002;272(2):93-108.
31. Yamaguchi H, Condeelis, J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007;1773(5):642-652.
32. Peckham M, Miller G, Wells C, Zicha D, Dunn, G. A. Specific changes to the mechanism of cell locomotion induced by overexpression of beta-actin. J Cell Sci 2001;114:1367-1377.
33. Le PU, Nguyen TN, Drolet-Savoie, P., Leclerc N, Nabi, I. R. Increased beta-actin expression in an invasive moloney sarcoma virus-transformed MDCK cell variant concentrates to the tips of multiple pseudopodia. Cancer Res 1998;58(8):1631-1635.
34. Nguyen TN, Wang HJ, Zalzal S, Nanci A, Nabi, I. R. Purification and characterization of beta-actin-rich tumor cell pseudopodia: role of glycolysis. Exp Cell Res 2000;258(1):171-183.
35. Andreeva L, Heads R, Green, C. J. Cyclophilins and their possible role in the stress response. Int J Exp Pathol 1999;80(6):305-315.
36. Bourquin JP, Stagljar I, Meier P, Moosmann P, Silke J, Baechi T, Georgiev O, Schaffner, W. A serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase II. Nucleic Acids Res 1997;25(11):2055-2061.
37. Bian XW, Xu JP, Ping YF, Wang Y, Chen JH, Xu CP, Wu YZ, Wu J, Zhou XD, Chen YS, Shi JQ, Wang, J. M. Unique proteomic features induced by a potential antiglioma agent, Nordy (dl-nordihydroguaiaretic acid), in glioma cells. Proteomics 2008;8(3):484-494.
38. Chen JX, Gao Y, Liu JW, Tian YX, Zhao J, Cui, X. Y. Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells. Int J Biochem Cell Biol 2005;37(6):1219-1231.
39. Ando S, Tanabe K, Gonda Y, Sato C, Inagaki, M. Domain-and sequence-specific phosphorylation of vimentin induces disassembly of the filament structure. Biochemistry 1989;28(7):2974-2979.
40. Chou YH, Ngai KL, Goldman, R. The regulation of intermediate filament reorganization in mitosis. p34cdc2 phosphorylates vimentin at a unique N-terminal site. J Biol Chem 1991;266(12):7325-7328.
41. Huang TJ, Lee TT, Lee WC, Lai YK, Yu JS, Yang, S. D. Autophosphorylation- dependent protein kinase phosphorylates Ser25, Ser38, Ser65, Ser71, and Ser411 in vimentin and thereby inhibits cytoskeletal intermediate filament assembly. J Protein Chem 1994;13(6):517-525.
42. Shirahata A, Sakata M, Sakuraba K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi, K. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res 2009;29(1):279-281.
43. Katsumoto T, Mitsushima A, Kurimura, T. The role of the vimentin intermediate filaments in rat 3Y1 cells elucidated by immunoelectron microscopy and computer-graphic reconstruction. Biol Cell 1990;68(2):139-146.
44. Thoumine O, Ziegler T, Girard PR, Nerem, R. M. Elongation of confluent endothelial cells in culture: the importance of fields of force in the associated alterations of their cytoskeletal structure. Exp Cell Res 1995;219(2):427-441.
45. Wang N, Butler JP, Ingber, D. E. Mechanotransduction across the cell surface and through the cytoskeleton. Science 1993;260(5111):1124-1127.
46. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson, P. H. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61(13):5168-5178.
47. Penuelas S, Noe V, Ciudad, C. J. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J 2005;272(3):696-710.
48. Trog D, Fountoulakis M, Friedlein A, Golubnitschaja, O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 2006;6(9):2924-2930.
49. Zhang MH, Lee JS, Kim HJ, Jin DI, Kim JI, Lee KJ, Seo, J. S. HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis. Mol Cell Biochem 2006;281(1-2): 111-121.
50. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor, R. E. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev 1996;15(4):507-525.
51. Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, Huang M, Wang Y, Wu MC, Huang JF, Zeng WF, Sham JS, Yang M, Guan, X. Y. Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004;23(1):298-302.
52. Trog D, Yeghiazaryan K, Schild HH, Golubnitschaja, O. Upregulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment. Amino Acids 2008;34(4):539-545.